GXMC
BPMC

Global X Management Company’s Blueprint Medicines BPMC Stock Holding History

Global X Management Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$37K Sell
575
-138
-19% -$11K ﹤0.01% 1153
2018
Q1 		$65K Buy
713
+180
+34% +$15.5K ﹤0.01% 986
2017
Q4 		$40K Buy
533
+120
+29% +$8.44K ﹤0.01% 943
2017
Q3 		$29K Buy
413
+60
+17% +$3.21K ﹤0.01% 999
2017
Q2 		$18K Buy
+353
New +$15K ﹤0.01% 1166

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Global X Management Company's BPMC Position: Q2 2018 in Review

Global X Management Company reduced its Blueprint Medicines (BPMC) stake by 19% in Q2 2018, selling an estimated $11K and leaving 575 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

Global X Management Company first reported a position in BPMC in Q2 2017 and has held it in 5 quarters since. The position peaked at $65K in Q1 2018. 181 funds tracked by Wall St. Rank hold BPMC as of Q2 2018.

  • Global X Management Company held 575 shares of Blueprint Medicines worth $37K as of Q2 2018.
  • Global X Management Company sold 138 Blueprint Medicines shares in Q2 2018, an estimated $11K.
  • Blueprint Medicines made up ﹤0.01% of Global X Management Company's portfolio in Q2 2018, its #1153 holding.
  • Global X Management Company first reported a position in Blueprint Medicines in Q2 2017 and has held it in 5 quarters since.
  • Global X Management Company's Blueprint Medicines position peaked at $65K in Q1 2018.
  • 181 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.